Khan Anis, Kurbanov Fuat, Tanaka Yasuhito, Elkady Abeer, Sugiyama Masaya, Dustov Abdusamad, Mizokami Masashi
Department of Clinical Molecular Informative Medicine, Nagoya City University Graduate School of Medical Sciences, Kawasumi, Mizuho, Nagoya, Japan.
J Med Virol. 2008 Feb;80(2):268-76. doi: 10.1002/jmv.21057.
The implication of genotypes is recognized increasingly in the clinical course of hepatitis B virus (HBV) and in response to anti-viral drugs of hepatitis C virus (HCV). Genotypic prevalence of both etiological agents varies geographically and no data are available for Tajikistan. To investigate the epidemiology and clinical significance of HBV and HCV genotypes in chronic hepatitis (group 1) and liver cirrhosis/hepatocellular carcinoma (HCC) (group 2) patients in Tajikistan, 124 patients with chronic liver disease (group 1 = 84 and group 2 = 40) were enrolled. Genotypes of HBV, HCV, and delta hepatitis virus (HDV) were determined by sequencing. The overall prevalence of anti-HCV, HCV core antigen (HCVcAg) and HBsAg was 46% (57/124) and 41.1% (51/124), respectively. Coinfection of HCV/HBV, HBV/HDV, and HCV/HBV/HDV was found in 4.8% (6/124), 11.2% (12/124), and 0.8% (1/124) of cases, respectively. HDV genotype 1 was found in 19.6% (10/51) of HBsAg-positive patients. The HBV/HDV coinfection was relatively high in group 2 compared to group 1 (15% vs. 7.1%). HCV/1b detected in 84.6% (44/52) of HCV RNA-positive patients, followed by 3a (7.6%), 2a (5.7%), and 2c (1.9%). HBV/D was detected in 94.1% (48/51) of HBsAg-positive patients, followed by HBV/A [5.8% (3/51)]. T1762/A1764 double mutation was associated with liver cirrhosis/HCC in HBV-infected patients (P = 0.0004). This is the first study on the molecular epidemiology of hepatitis viruses among chronic liver diseases patients in Tajikistan. Among HBV-infected patients, the T1762/A1764 mutation was associated with liver cirrhosis/HCC.
在乙型肝炎病毒（HBV）的临床病程以及丙型肝炎病毒（HCV）对抗病毒药物的反应中，基因型的影响越来越受到认可。这两种病原体的基因型流行情况在地理上存在差异，而塔吉克斯坦尚无相关数据。为了调查塔吉克斯坦慢性肝炎患者（第1组）和肝硬化/肝细胞癌（HCC）患者（第2组）中HBV和HCV基因型的流行病学及临床意义，纳入了124例慢性肝病患者（第1组 = 84例，第2组 = 40例）。通过测序确定HBV、HCV和丁型肝炎病毒（HDV）的基因型。抗-HCV、HCV核心抗原（HCVcAg）和HBsAg的总体流行率分别为46%（57/124）和41.1%（51/124）。HCV/HBV、HBV/HDV和HCV/HBV/HDV的合并感染分别在4.8%（6/124）、11.2%（12/124）和0.8%（1/124）的病例中发现。在HBsAg阳性患者中，19.6%（10/51）发现HDV基因型1。与第1组相比，第2组中HBV/HDV合并感染相对较高（15%对7.1%）。在HCV RNA阳性患者中，84.6%（44/52）检测到HCV/1b，其次是3a（7.6%）、2a（5.7%）和2c（1.9%）。在HBsAg阳性患者中，94.1%（48/51）检测到HBV/D，其次是HBV/A [5.8%（3/51）]。T1762/A1764双突变与HBV感染患者的肝硬化/HCC相关（P = 0.0004）。这是塔吉克斯坦首次针对慢性肝病患者进行的肝炎病毒分子流行病学研究。在HBV感染患者中，T1762/A1764突变与肝硬化/HCC相关。
